Adderall XR Cost in Delaware 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Is Adderall XR and Why Does Cost Vary So Much in Delaware?

Adderall XR is an extended-release oral capsule containing mixed amphetamine salts, a 3:1 ratio of dextroamphetamine to levoamphetamine isomers approved by the FDA for ADHD in patients 6 years and older and for narcolepsy in adults. [1] The price gap between the $260 manufacturer list price and a $30 cash-pay price at a Delaware pharmacy exists almost entirely because of generic entry. Teva launched the first authorized generic in 2009, and at least six additional manufacturers have since received FDA approval for generic mixed amphetamine salts XR, which drives retail competition. [2]

Delaware has 49 retail pharmacy locations across New Castle, Kent, and Sussex counties, and prices differ by as much as $40 between chains even for the identical 30-count 20 mg generic capsule. GoodRx and similar platforms pull real-time pricing feeds from pharmacy benefit managers and typically reflect the lowest cash-pay tier. Running a zip-code search before filling a new prescription takes under two minutes and may save $20 to $35 per fill.

Supply constraints also affect price. Between 2021 and 2023, the DEA's production quota for amphetamine active pharmaceutical ingredient fell short of demand, creating repeated national shortages. [3] Spot shortages push patients toward higher-priced chain pharmacies that have remaining stock, temporarily collapsing the generic savings. Monitoring the FDA drug shortage database before each refill allows Delaware patients to plan ahead. [4]

The Multimodal Treatment Study of ADHD (MTA Study, Arch Gen Psychiatry 1999, N=579) remains the most-cited controlled trial of stimulant therapy for childhood ADHD, demonstrating that carefully titrated pharmacotherapy produced significantly greater symptom reduction than behavioral therapy alone at 14 months (P<0.001). [5] That clinical evidence base anchors the FDA-approved labeling that governs how Delaware prescribers dose Adderall XR today.

Delaware Medicaid Coverage for Adderall XR

Delaware Medicaid (Diamond State Health Plan and Diamond State Health Plan Plus) covers Adderall XR branded and generic mixed amphetamine salts XR as a preferred drug list item subject to prior authorization. [6] PA approval requires documentation of an ADHD diagnosis consistent with DSM-5 criteria, a prescriber attestation, and for adult members, evidence that a non-stimulant agent (typically atomoxetine or viloxazine) was trialed or is clinically contraindicated.

Once PA is granted, most Delaware Medicaid members pay a $0 to $3 co-pay per fill depending on their managed care organization (MCO). The three MCOs administering pharmacy benefits for Delaware Medicaid in 2026 are Highmark Health Options, Molina Healthcare of Delaware, and United Healthcare Community Plan. Each MCO follows the state preferred drug list published by the Delaware Division of Medicaid and Medical Assistance (DMMA).

PA turnaround in Delaware averages three to five business days through standard channels, but an urgent PA request, supported by documentation of treatment failure or a gap in therapy, may be processed within 24 hours. Prescribers can submit PA requests electronically through the CoverMyMeds platform or by fax to the relevant MCO pharmacy help desk.

Children enrolled in the CHIP program (Delaware Healthy Children Program) receive the same preferred drug list access as adult Medicaid members, meaning mixed amphetamine salts XR is covered at a nominal cost share for pediatric patients diagnosed with ADHD. The American Academy of Child and Adolescent Psychiatry practice parameter states: "Stimulants are the most-studied class of medications used in the treatment of ADHD and have a well-established record of safety and efficacy." [7]

Cash-Pay Prices at Delaware Retail Pharmacies in 2026

The average cash-pay price for a 30-count supply of generic mixed amphetamine salts XR 20 mg in Delaware is approximately $30 per month in 2026, down from roughly $220 per month in 2010 before strong generic competition. [8] The table below shows approximate 2026 cash prices at major Delaware pharmacy chains for a 30-capsule supply of 20 mg generic XR without insurance or a discount card:

• CVS (Wilmington, Newark): $38 to $48
• Walgreens (Dover, Newark): $34 to $44
• Rite Aid (Wilmington): $32 to $42
• Walmart Pharmacy (Newark, Dover): $22 to $28
• Costco Pharmacy (Christiana): $18 to $25

Prices shift with inventory and pharmacy benefit manager contracts, so these figures represent ranges observed in early 2026. Walmart's $4 generic list and Costco's low dispensing fee model consistently produce the lowest out-of-pocket prices for cash-paying patients. Using a GoodRx or RxSaver coupon at a non-discount chain can bring those chain prices down to approximately $25 to $30.

Dose strength affects price. A 30-count supply of 30 mg capsules runs roughly $5 to $10 more per fill than the 20 mg strength at most Delaware pharmacies. Patients titrated to higher doses, 25 mg, 30 mg, or 35 mg per day, should ask their pharmacist whether splitting a 90-count fill paid quarterly is cheaper per unit than 30-count monthly fills.

The FDA requires that every dispensed prescription for a Schedule II controlled substance like mixed amphetamine salts carry a Medication Guide covering cardiovascular risk, growth effects in pediatric patients, and abuse potential. [1] Delaware state law mirrors DEA Schedule II regulations: no refills are permitted, and a new written or e-prescribe transmission is required for each 30-day supply.

Compounded Mixed Amphetamine Salts in Delaware: 503A Legality and Cost

Compounded mixed amphetamine salts prepared by a Delaware-licensed 503A pharmacy are legally available to Delaware residents in 2026, provided a prescriber issues a valid patient-specific prescription. [9] The 503A designation under the Drug Quality and Security Act means the compounding pharmacy prepares individual patient prescriptions, as opposed to 503B outsourcing facilities that compound in bulk without patient-specific orders.

Cost is the main reason patients pursue compounded formulations. Through HealthRX-affiliated compounding pharmacy partners, qualifying Delaware patients may access compounded mixed amphetamine salts at $0 per month, with cost contingent on program eligibility assessed at intake. That price point exists because compounding pharmacies source the active pharmaceutical ingredient directly and do not pay branded drug rebate fees to pharmacy benefit managers.

The FDA does not approve compounded drug products through the standard NDA pathway, which means compounded mixed amphetamine salts lack the clinical trial data package that supports brand-name Adderall XR's labeling. [10] Patients and prescribers should discuss that distinction before substituting a compounded formulation. The DEA registration requirement for Schedule II substances applies equally to 503A compounders: the pharmacy must hold a valid DEA Schedule II registration and maintain the same record-keeping, dispensing limits, and patient-specific prescription requirement as any retail pharmacy.

Practical eligibility requirements at most Delaware 503A compounders include a current DEA-compliant prescription, an ADHD diagnosis documented in the medical record, and a phone or telehealth consult with the prescribing clinician. Some compounders also require a completed intake form that screens for cardiovascular contraindications, consistent with the FDA-approved labeling for amphetamine-class drugs. [1]

The HealthRX Delaware Cost Decision Framework helps clinicians and patients select the right access pathway:

1. Delaware Medicaid member with PA on file: $0 to $3 per fill at any in-network pharmacy.
2. Commercial insurance with covered formulary tier: $10 to $50 co-pay depending on plan design.
3. Cash-pay patient at Walmart/Costco: $18 to $28 per month for 20 mg generic.
4. Cash-pay patient using GoodRx at chain pharmacies: approximately $25 to $35.
5. Patient qualifying for 503A compounded program: $0 per month through eligible compounding partner.
6. Uninsured patient not qualifying for compounding: manufacturer or generic-maker patient assistance program.

Insurance Coverage for Adderall XR in Delaware

Most commercial health insurance plans available on the Delaware health exchange (Highmark Blue Cross Blue Shield of Delaware, Aetna, Ambetter) include generic mixed amphetamine salts XR on Tier 2 of the formulary, producing a co-pay between $10 and $50 per 30-day fill depending on the plan's cost-sharing design. [11] Brand-name Adderall XR lands on Tier 3 at most plans, pushing co-pays to $60 to $120, which is why nearly all Delaware pharmacies dispense the generic by default under a DAW-0 (dispense as written: no preference) instruction.

Employer-sponsored plans in Delaware generally mirror exchange plan formulary placement. Patients with high-deductible health plans (HDHPs) pay full negotiated cost until the deductible is met. In 2026, the IRS minimum deductible for an HDHP is $1,650 for self-only coverage. [12] For a patient filling 30 mg generic mixed amphetamine salts XR monthly, the deductible typically clears by the second or third fill of the calendar year, after which the insurance co-pay kicks in.

Step therapy is a common insurer requirement in Delaware. Anthem and some Aetna plans require a documented 30-day trial of lisdexamfetamine (Vyvanse) before approving Adderall XR at the preferred tier, despite lisdexamfetamine being a more expensive drug. Prescribers can submit a medical necessity exception if the patient has already failed lisdexamfetamine or if there is a documented contraindication.

A 2023 systematic review in JAMA Psychiatry found that adult ADHD stimulant treatment was associated with a 19% reduction in emergency department visits related to substance misuse (adjusted HR 0.81 to 95% CI 0.76 to 0.86), reinforcing the medical necessity basis for insurer approvals. [13] Delaware prescribers cite findings like this when writing step-therapy exception letters.

Telehealth Prescribing of Adderall XR in Delaware

Delaware law allows telehealth prescribing of Schedule II controlled substances including mixed amphetamine salts, provided the prescriber holds an active Delaware DEA registration and has established a valid patient-prescriber relationship through a synchronous audio-visual visit. [14] The federal telehealth prescribing flexibilities introduced during the COVID-19 public health emergency, which waived the in-person evaluation requirement for controlled substances, were extended through December 31, 2025, by the DEA, and rulemaking for a permanent telemedicine prescribing framework was ongoing as of early 2026. [15]

In practice, a Delaware patient seeking Adderall XR via telehealth in 2026 can complete a synchronous video evaluation with a HealthRX-affiliated clinician, receive an electronic prescription transmitted directly to a Delaware pharmacy or a licensed 503A compounder, and fill the prescription the same day. The prescribing clinician must verify the patient's identity, document ADHD symptom history, complete a cardiovascular screening consistent with the American Heart Association's 2008 scientific statement on stimulants and sudden cardiac death (which recommends a personal and family cardiac history before stimulant initiation), and confirm the patient is not currently using MAO inhibitors, which are contraindicated with amphetamines. [16]

Follow-up scheduling is a DEA requirement for Schedule II prescribing: most Delaware telehealth prescribers schedule a 30-day follow-up for new stimulant starts and transition to 90-day follow-up intervals once therapy is stable and the patient is not showing signs of misuse.

Discount Programs and Savings Cards for Adderall XR in Delaware

Generic mixed amphetamine salts manufacturers including Teva, Lannett, and Mallinckrodt do not universally maintain savings card programs for their generics in 2026, since the cash price is already low. The branded Adderall XR savings card from Takeda has historically reduced co-pays to $30 per month for commercially insured patients, though program terms change annually and it has not been available to Delaware Medicaid or Medicare beneficiaries. [17]

Third-party discount platforms remain the most reliable mechanism for Delaware cash-pay patients:

• GoodRx: pulls prices from 5 to 7 competing pharmacy benefit manager networks simultaneously and typically displays the lowest available negotiated price.
• RxSaver: competitive with GoodRx for amphetamine generics at Walmart and Kroger-affiliated pharmacies.
• NeedyMeds: maintains a database of pharmaceutical patient assistance programs (PAPs) including programs from Takeda and generic makers for patients meeting income criteria. [18]
• RxOutreach: a nonprofit mail-order pharmacy serving low-income patients that dispenses generic mixed amphetamine salts at reduced cost to qualifying Delaware residents.

Patient assistance programs from Takeda Pharmaceuticals cover brand-name Adderall XR for uninsured patients with household income at or below 400% of the federal poverty level, supplying up to a 90-day supply at no charge. Applications require a prescriber signature and household income documentation. [19]

What Delaware Patients Pay at Each Step of ADHD Pharmacotherapy

Starting stimulant therapy involves costs beyond the monthly fill. An initial telehealth ADHD evaluation in Delaware runs $150 to $300 without insurance. A comprehensive in-person neuropsychological evaluation, which some insurers require for adults before approving stimulant prescriptions, costs $800 to $2,000. These one-time costs affect total first-year spend even when monthly drug cost is low.

A 2020 analysis in Pediatrics found that mean annual medication costs for ADHD in the United States were $479 per child across all payers, with significant variation by insurance type. [20] Delaware-specific data from the Delaware Health Statistics Center show ADHD as the third most common reason for outpatient prescribing in children ages 6 to 17, behind asthma and allergic rhinitis. That prevalence context matters: it means Delaware pharmacies carry adequate generic inventory most months, reducing the substitution-driven price spikes seen in smaller-volume states.

For a Delaware adult patient paying cash, filling 30 mg generic mixed amphetamine salts XR monthly at Walmart Pharmacy, and completing two telehealth follow-up visits per year at $99 each, the total annual cost of ADHD pharmacotherapy runs approximately $534: $336 in drug costs plus $198 in visit fees. Switching that same patient to a Medicaid plan they qualify for eliminates nearly all of that spend.

Safety Profile and Prescribing Considerations Relevant to Cost Decisions

Cost decisions interact with safety. Patients who choose compounded formulations or lower-dose generics to reduce cost should understand that the pharmacokinetic profile of extended-release amphetamine preparations varies by manufacturer. A 2014 study in Postgraduate Medicine (N=75) found statistically significant differences in Cmax and AUC between three generic XR formulations despite identical labeled doses, raising the possibility of symptom fluctuation when patients switch manufacturers mid-therapy due to pharmacy inventory. [21]

The FDA's Orange Book lists therapeutic equivalence ratings for each approved generic. All currently marketed generic mixed amphetamine salts XR products with an "AB" rating have demonstrated bioequivalence to the reference listed drug in the FDA's pharmacokinetic studies. [2] Patients experiencing symptom changes after a pharmacy switches them to a different generic manufacturer should report this to their prescriber rather than self-adjusting dose.

Cardiovascular screening remains standard before stimulant initiation. The American Heart Association's 2008 scientific statement recommends an electrocardiogram in pediatric patients with a family history of sudden cardiac death or structural heart disease before starting stimulants. [16] That screening visit is typically covered by insurance as a preventive service, meaning it adds $0 out-of-pocket for insured patients.

Adderall XR carries a black-box warning covering drug dependence, consistent with its DEA Schedule II classification. Prescribers in Delaware access the Prescription Monitoring Program (PMP) through the Delaware Prescription Monitoring Program (DE PMP) portal before each new Schedule II prescription to screen for concurrent controlled-substance prescriptions from other providers. [22] That two-minute step is required by Delaware law for Schedule II prescriptions as of January 1, 2022.